articleTop 1% cited

Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts

Clinical Cancer Research · 2016 · Vol. 22(16) · pp. 4215–4224

Ellen Stelloo✉(Leiden University Medical Center)Remi A. Nout(Leiden University Medical Center)Elisabeth M. Osse(Leiden University Medical Center)Ina J. Jürgenliemk-Schulz(University Medical Center Utrecht)Jan J. Jobsen(Medisch Spectrum Twente)Ludy Lutgens(Maastro Clinic)Elzbieta M. van der Steen‐Banasik(Radiotherapiegroep)Hans W. Nijman(University Medical Center Groningen)Hein Putter(Leiden University Medical Center)Tjalling Bosse(Leiden University Medical Center)Carien L. Creutzberg(Leiden University Medical Center)Vincent T.H.B.M. Smit(Leiden University Medical Center)

View via DOI Publisher page

Abstract

Integrating clinicopathologic and molecular factors improves the risk assessment of patients with early-stage endometrial carcinoma. Assessment of this integrated risk profile is feasible in daily practice, and holds promise to reduce both overtreatment and undertreatment. Clin Cancer Res; 22(16); 4215-24. ©2016 AACR.

Endometrial and Cervical Cancer Treatments Ovarian cancer diagnosis and treatment Cervical Cancer and HPV ResearchMicrosatellite instabilityEndometrial cancerOncologyPTENInternal medicineLymphovascular invasionStage (stratigraphy)MedicineHazard ratioAdjuvant therapy

MeSH terms

Poly-ADP-Ribose Binding ProteinsAdultAgedAged, 80 and overDNA Polymerase IIFemaleHumansMiddle AgedMutationNeoplasm StagingPrognosisRecurrenceBiomarkers, TumorSurvival AnalysisRandomized Controlled Trials as Topic